Supplementary Figure 8: Relationship between the MES and ADRN signature scores and molecular and clinical variables and the prognostic value of PRRX1 in a series of 122 primary neuroblastoma tumors.
From: Neuroblastoma is composed of two super-enhancer-associated differentiation states
(a) HE staining of tumor N712T, which is a highly mesenchymal neuroblastoma as indicated in b, shows ~90% tumor cell content. (b–h) Mesenchymal and adrenergic signature scores in primary neuroblastoma tumors in relation to percentage tumor cells in sections used for mRNA profiling (b), amplification of MYCN (c), LOH1p (d), loss of chromosome 11 (e), INSS stage (f), survival (g) and age (h). Box plots show the median signature score for each group. Whiskers denote the interval within 1.5 times the interquartile range (IQR) of the median. Tumors for which parameters were not determined are not shown in b–h. Cell line pairs are numbered 1–4 with MES and ADRN counterparts shown in orange and blue, respectively. (i–l) Kaplan–Meier analysis of the relationship between PRRX1 expression and overall survival in a series of 122 neuroblastoma tumors (i,j) and a neuroblastoma series analyzed by RNA–seq (k,l). Patients were classified in two groups with PRRX1 expression above or below the median value. The analysis was performed for all patients in the series (i,k) or for stage 3 and 4 patients only (j,l).
